nice.org.uk

GENERAL
META
HTML
LINK ANALYSIS
SERVER
IP

Nice.org.uk receives any estimated 114,300 unique visitors and 418,292 unique page views per day. Revenue gained from these much visits may be $296 per day from various advertising sources. The estimated worth of site is $248,905. Alexa global rank is 16,345. Maximum no. of users comes from UNITED KINGDOM. Rank in UNITED KINGDOM is 656.

Amazon Technologies Inc is ISP, hosted on IP 52.218.108.44 in Country Ireland.

Website Age n/a
Alexa Rank no-data
Country Ireland
IP Address 52.218.108.44

META INFORMATION

Title

NICE | The National Inst**ute for Health and Care Excellence

Description

Guidance, advice and information services for health, public health and social care professionals.

Keywords

Content Type

utf-8

No	Meta Name	Value
1	viewport	width=device-width, initial-scale=1

google ads

GENERAL HTML INFORMATION

Type	Status
HTML 5
Responsive Website

HTML SIZE INFORMATION

Text / Code Ratio 11.97 %

nice.org.uk has a website text/code ratio of 11.97 %. Search engine crawlers tend to not pick up pages with inadequate content.

IMPORTANT HTML TAGS AND COUNTS

Titles

No	Text
1	ımproving health and social care through evidence-based guidance

No	Text
1	Latest guidance
2	Latest guidance in consultation

No	Text
1	Browse guidance by area:
2	Explore nıce
3	Latest news
4	Tweets

Text Styling

STRONG1
B0
EM0
I0
U0
CITE0

STRONG

No	Text
1	Explore NICE

LINK ANALYSIS

Total Link Count: 43

Internal Link Count : 40

No	Text	Type
1	Find NICE guidance	text
2	Conditions and diseases	text
3	Health and social care delivery	text
4	Health protection	text
5	Lifestyle and wellbeing	text
6	Pop****tion groups	text
7	Settings	text
8	About us	text
9	Put guidance into practice	text
10	Find journals and databases	text
11	Financial planning	text
12	Get involved	text
13	Latest guidance	text
14	Larotrectinib for treating NTRK fusion-positive solid tumours	text
15	COVID 19 rapid evidence summary: Anakinra for COVID-19 a***ociated secondary haemophagocytic lymphohistiocytosis	text
16	COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19	text
17	COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19	text
18	Cytokine adsorption devices for treating respiratory failure in people with COVID-19	text
19	Latest guidance in consultation	text
20	News	text
21	About	text
22	Events	text
23	Get involved	text
24	-	image
25	Find out more about working for us	text
26	-	image
27	Find resources to help you put guidance into practice	text
28	-	image
29	View our antimicrobial prescribing guidelines	text
30	-	image
31	Support for industry to engage with us during health technology development	text
32	-	image
33	Watch our video about how we're reviewing the way we produce and present guidance	text
34	-	image
35	How we're supporting the NHS and social care to respond quickly to the challenges of the COVID-19 pandemic	text
36	Latest news	text
37	NICE recommends treatment for type of small-cell lung cancer	text
38	NICE chairman Sharmila Nebhrajani begins her new role	text
39	Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE	text
40	NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interst**ial lung disease	text